BusinessIndustries

Global Human Coagulation Factor VIII market is valued at 7440 million US$ in 2018 is expected to reach 9420 million US$ by the end of 2025, growing at a CAGR of 3.0% during 2019-2025

Global Human Coagulation Factor VIII Market Research Report 2019

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.
North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.

The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from regions.

Asia is an important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from regions.

Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.

Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.

The global Human Coagulation Factor VIII market is valued at 7440 million US$ in 2018 is expected to reach 9420 million US$ by the end of 2025, growing at a CAGR of 3.0% during 2019-2025.
This report focuses on Human Coagulation Factor VIII volume and value at global level, regional level and company level. From a global perspective, this report represents overall Human Coagulation Factor VIII market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The report includes an in-depth analysis of the competitive landscape of this business vertical, constituting manufacturers like:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS

Market Segment by Regions includes:
North America
Europe
China
Japan

Products Segmentation, this report displays the production, revenue, price, market share, and growth rate of each type as below:
Recombinant Factor VIII
Plasma-derived Factor VIII

By Industrial Application, the market can be split into:
Hemophilia A
Spontanous / Trauma
Surgical

Market Segment by Regions includes:

  • North America (the USA, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, and Italy)
  • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  • South America
  • Middle East and Africa.

Browse contents of Global Human Coagulation Factor VIII Market Research Report 2019

Contacts

Trusted Business Insights
Joseph Anthony Jones
Senior Media & Marketing Executive
US: +1 646 568 9797
UK: +44 330 808 0580

Tags

Related Articles

Close